Prova Education: Changing the Practice of Medicine - Prova Education

Changing the Practice of Medicine

Changing the Practice of Medicine

Discover CME, tools, and guideline-focused education to
improve your knowledge - and patient outcomes.

Popular

Translating Research Into Practice in Breast Cancer: Emerging Data and the Expanding Role of ADCs
Translating Research Into Practice in Breast Cancer: Emerging Data and the Expanding Role of ADCs
CME/CE
Translating Research Into Practice in Breast Cancer: Emerging Data and the Expanding Role of ADCs
Sara A. Hurvitz, MD, FACP; Tiffany Traina, MD
0.50 credits
- Sara A. Hurvitz, MD, FACP
- Tiffany Traina, MD
0.50 credits
Clinical Evidence on Emerging Antigen-Directed Strategies in ES-SCLC
Clinical Evidence on Emerging Antigen-Directed Strategies in ES-SCLC
MinuteCE®
Clinical Evidence on Emerging Antigen-Directed Strategies in ES-SCLC
Ticiana Leal, MD
0.50 program credits
- Ticiana Leal, MD
0.50 program credits
MinuteCE®
Beyond Checkpoint Blockade in SCLC: Emerging Antigen Targets and Treatment Strategies Across Disease Stages
Neal Ready, MD, PhD; Ticiana Leal, MD
0.50 credits 4 episodes
- Neal Ready, MD, PhD
- Ticiana Leal, MD
0.50 credits 4 episodes
Advancing Acromegaly Care: Diving Deeper Into Diagnosis, Guideline Application, and Emerging Therapies—A Fireside Chat With Expert Perspectives
Advancing Acromegaly Care: Diving Deeper Into Diagnosis, Guideline Application, and Emerging Therapies—A Fireside Chat With Expert Perspectives
CME/CE Broadcast Replay
Advancing Acromegaly Care: Diving Deeper Into Diagnosis, Guideline Application, and Emerging Therapies—A Fireside Chat With Expert Perspectives
Maria Fleseriu, MD, FACE; Beverly MK Biller, MD, FACP
1.50 credits
- Maria Fleseriu, MD, FACE
- Beverly MK Biller, MD, FACP
- Mark Gurnell, MD
1.50 credits
CME/CE Virtual Event
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
Multiple dates available
1.00 credit
From Data to Decision: Patient Selection and Real-World Application
From Data to Decision: Patient Selection and Real-World Application
MinuteCE®
From Data to Decision: Patient Selection and Real-World Application
Christophe Le Tourneau, MD, PhD; Marc Oliva, MD, PhD
0.50 program credits
- Christophe Le Tourneau, MD, PhD
- Marc Oliva, MD, PhD
0.50 program credits
MinuteCE®
Perioperative Immunotherapy in LA-HNSCC: From Evidence to Clinical Practice
Christophe Le Tourneau, MD, PhD; Marc Oliva, MD, PhD
0.50 credits 4 episodes
- Christophe Le Tourneau, MD, PhD
- Marc Oliva, MD, PhD
0.50 credits 4 episodes
Building the Team: Integrating Immunotherapy Into Multidisciplinary Care
Building the Team: Integrating Immunotherapy Into Multidisciplinary Care
MinuteCE®
Building the Team: Integrating Immunotherapy Into Multidisciplinary Care
Christophe Le Tourneau, MD, PhD; Marc Oliva, MD, PhD
0.50 program credits
- Christophe Le Tourneau, MD, PhD
- Marc Oliva, MD, PhD
0.50 program credits

CME/CE

CME/CE Virtual Event
Closing the Gap in First-Line Treatment of KRAS G12C–Mutated Advanced NSCLC: From Biology to Bedside Decisions and Trial-Ready Care
Multiple dates available
0.75 credits
CME/CE In-Person & Virtual Event
The CELMoD Shift: Translating Protein Degradation Science Into Practice-Changing Myeloma Care
December 11, 2026
New Orleans, Louisiana
1.50 credits
On the Horizon: Emerging Antigen-Directed Strategies Across Disease Stage
On the Horizon: Emerging Antigen-Directed Strategies Across Disease Stage
MinuteCE®
On the Horizon: Emerging Antigen-Directed Strategies Across Disease Stage
Ticiana Leal, MD
0.50 program credits
- Ticiana Leal, MD
0.50 program credits
The Evidence Base: Key Trials and Emerging Data
The Evidence Base: Key Trials and Emerging Data
MinuteCE®
The Evidence Base: Key Trials and Emerging Data
Christophe Le Tourneau, MD, PhD; Marc Oliva, MD, PhD
0.50 program credits
- Christophe Le Tourneau, MD, PhD
- Marc Oliva, MD, PhD
0.50 program credits
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
MinuteCE®
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
Aditya Bardia, MD, MPH, FASCO; Erica L. Mayer, MD, MPH
0.50 program credits
- Aditya Bardia, MD, MPH, FASCO
- Erica L. Mayer, MD, MPH
0.50 program credits
Precision in Practice—Bringing Targeted Therapy to mHSPC
Precision in Practice—Bringing Targeted Therapy to mHSPC
MinuteCE®
Precision in Practice—Bringing Targeted Therapy to mHSPC
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit

Clinical Practice

Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
CME/CE In-Person Event
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
September 18, 2026
Palo Alto, California
1.50 credits
Rationale of Emerging Antigen-Directed Strategies in Frontline ES-SCLC
Rationale of Emerging Antigen-Directed Strategies in Frontline ES-SCLC
MinuteCE®
Rationale of Emerging Antigen-Directed Strategies in Frontline ES-SCLC
Neal Ready, MD, PhD
0.50 program credits
- Neal Ready, MD, PhD
0.50 program credits
The Case for Change: Why Perioperative Immunotherapy Matters in LA HNSCC
The Case for Change: Why Perioperative Immunotherapy Matters in LA HNSCC
MinuteCE®
The Case for Change: Why Perioperative Immunotherapy Matters in LA HNSCC
Christophe Le Tourneau, MD, PhD; Marc Oliva, MD, PhD
0.50 program credits
- Christophe Le Tourneau, MD, PhD
- Marc Oliva, MD, PhD
0.50 program credits
ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
MinuteCE®
ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
In-Person & Virtual Event
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
September 12, 2026
Seoul
What’s Next for TROP2-Directed ADCs in TNBC?
What’s Next for TROP2-Directed ADCs in TNBC?
MinuteCE®
What’s Next for TROP2-Directed ADCs in TNBC?
Tiffany Traina, MD
0.75 program credits
- Tiffany Traina, MD
0.75 program credits

Programs

From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
MinuteCE®
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
Aditya Bardia, MD, MPH, FASCO; Erica L. Mayer, MD, MPH
0.50 program credits
- Aditya Bardia, MD, MPH, FASCO
- Erica L. Mayer, MD, MPH
0.50 program credits
Current Unmet Needs in First-Line Treatment of Metastatic TNBC
Current Unmet Needs in First-Line Treatment of Metastatic TNBC
MinuteCE®
Current Unmet Needs in First-Line Treatment of Metastatic TNBC
Javier Cortes, MD, PhD
0.75 program credits
- Javier Cortes, MD, PhD
0.75 program credits
Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
MinuteCE®
Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
Javier Cortes, MD, PhD
0.75 program credits
- Javier Cortes, MD, PhD
0.75 program credits
Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
MinuteCE®
Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
Tiffany Traina, MD
0.75 program credits
- Tiffany Traina, MD
0.75 program credits
MinuteCE®
Redefining First-Line Therapy of Metastatic TNBC: Integrating TROP2-Directed ADCs Into Modern Treatment Strategy
Tiffany Traina, MD; Javier Cortes, MD, PhD
0.75 credits 6 episodes
- Tiffany Traina, MD
- Javier Cortes, MD, PhD
0.75 credits 6 episodes
Case Consult: First-Line Treatment in Metastatic TNBC Ineligible for Immunotherapy
Case Consult: First-Line Treatment in Metastatic TNBC Ineligible for Immunotherapy
MinuteCE®
Case Consult: First-Line Treatment in Metastatic TNBC Ineligible for Immunotherapy
Tiffany Traina, MD; Javier Cortes, MD, PhD
0.75 program credits
- Tiffany Traina, MD
- Javier Cortes, MD, PhD
0.75 program credits